Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in advanced EGFR-mutant non-small cell lung cancer after prior EGFR TKI
jRCT2080222068Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222068.